Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs ONC

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:ONC)

BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Business Wire April 20, 2023

SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

GlobeNewswire April 17, 2023

BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

Business Wire April 17, 2023

MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

GlobeNewswire April 17, 2023

MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

Business Wire April 17, 2023

BeiGene Expands Presence in Latin America With Opening of Brazil Office

Business Wire April 13, 2023

BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity

Business Wire March 30, 2023

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

Business Wire March 21, 2023

BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire February 27, 2023

BeiGene to Present at Cowen's 43rd Annual Healthcare Conference

Business Wire February 24, 2023

BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China

Business Wire February 24, 2023

Quebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemia

Canada NewsWire February 6, 2023

New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care

Business Wire February 3, 2023

BeiGene to Present at Upcoming Investor Conferences

Business Wire February 1, 2023

BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia

Business Wire January 19, 2023

BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA

Business Wire January 19, 2023

BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List

Business Wire January 18, 2023

BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium

Business Wire January 17, 2023

BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference

Business Wire January 4, 2023

BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab

Business Wire December 30, 2022